Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718559 | 0.83 | APP (0.58) | APPMAPTADKGRM5PIK3CA | |
| SCHEMBL403731 | 0.82 | GRM5 (0.61) | APPMAPTADKGRM5MEN1 | |
| SCHEMBL864945 | 0.80 | APP (1.00) | APPMAPTADKPIK3CAMTOR | |
| SCHEMBL9611200 | 0.80 | APP (1.00) | APPMAPTADKPIK3CAMTOR | |
| SCHEMBL13499904 | 0.76 | HSP90AA1 (0.38) | APPMAPTGRM5MAP4K4 | |
| SCHEMBL3572562 | 0.75 | MAP4K4 (0.53) | GRM5PIK3CAMTORPDK1MAP4K4 | |
| SCHEMBL21903463 | 0.75 | APP (0.88) | APPMAPTPIK3CAMTORPDK1 | |
| SCHEMBL4717142 | 0.74 | APP (0.58) | APPMAPTADKPIK3CAMTOR | |
| SCHEMBL4716651 | 0.74 | LCK (0.46) | GRM5MAP4K4 | |
| SCHEMBL1951503 | 0.74 | APP (0.52) | APPMAPTADKPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| CN-1917879-A | Pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | APP 3484/4885MAPT 1508/4885ADK 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.